Koichiro Tatsumi
Overview
Explore the profile of Koichiro Tatsumi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
440
Citations
4619
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ikeda N, Masaki K, Hosokawa K, Funakoshi K, Taniguchi Y, Adachi S, et al.
Cardiovasc Interv Ther
. 2025 Jan;
PMID: 39841385
Advances in chronic thromboembolic pulmonary hypertension (CTEPH) treatment have improved prognosis, shifting focus towards symptom management. This study aimed to identify factors influencing the World Health Organization functional class (WHO-FC)...
2.
Suzuki Y, Kawasaki T, Tatsumi K, Okaya T, Sato S, Shimada A, et al.
Int J Mol Sci
. 2024 Dec;
25(23).
PMID: 39684311
In hypoxic pulmonary hypertension (PH), pulmonary vascular remodeling is characterized by the emergence of activated adventitial fibroblasts, leading to medial smooth muscle hyperplasia. Previous studies have suggested that CD26/dipeptidyl peptidase-4...
3.
Ohashi K, Nishito Y, Fukuda H, Sadahiro R, Yoshida Y, Watanabe S, et al.
Sci Rep
. 2024 Dec;
14(1):30457.
PMID: 39672904
No abstract available.
4.
Yanagisawa A, Kim J, Naito A, Kobayashi T, Misawa T, Sakao S, et al.
Sci Rep
. 2024 Nov;
14(1):27069.
PMID: 39511196
Pulmonary hypertension (PH) is a devastating disease characterized by vascular remodeling, resulting in right ventricular failure and death. Dysregulation of energy metabolism is linked to PH pathogenesis. Trimetazidine (TMZ), a...
5.
Nakamura J, Tsujino I, Masaki K, Hosokawa K, Funakoshi K, Taniguchi Y, et al.
J Heart Lung Transplant
. 2024 Nov;
44(3):339-348.
PMID: 39486772
Background: The management of chronic thromboembolic pulmonary hypertension (CTEPH) has advanced significantly in recent years, thereby improving patient prognosis. However, the impact of cancer on the outcomes of patients with...
6.
Masaki K, Hosokawa K, Funakoshi K, Taniguchi Y, Adachi S, Inami T, et al.
JACC Asia
. 2024 Aug;
4(8):577-589.
PMID: 39156509
Background: The contemporary outcome of balloon pulmonary angioplasty (BPA) and pulmonary endarterectomy (PEA) in patients with chronic thromboembolic pulmonary hypertension (CTEPH) are unclear. Objectives: This study aimed to clarify the...
7.
Ikari J, Katsumata M, Urano A, Imamoto T, Suzuki Y, Nishiyama A, et al.
BMJ Open Respir Res
. 2024 Aug;
11(1).
PMID: 39107000
Introduction: To date, there is limited evidence on the effects of bronchodilators on respiratory dynamics in chronic obstructive pulmonary disease (COPD). Dynamic chest radiography (DCR) is a novel radiographic modality...
8.
Sakuma N, Abe M, Ishii D, Kawasaki T, Arakawa N, Matsuyama S, et al.
BMC Pulm Med
. 2024 Jul;
24(1):364.
PMID: 39075455
Background: Serum levels of stratifin (SFN), a member of the 14-3-3 protein family, increase in patients with drug-induced lung injury associated with diffuse alveolar damage. Therefore, we hypothesised that SFN...
9.
Serum anti‑KIAA0513 antibody as a common biomarker for mortal atherosclerotic and cancerous diseases
Hiwasa T, Yoshida Y, Kubota M, Li S, Zhang B, Matsutani T, et al.
Med Int (Lond)
. 2024 Jul;
4(5):45.
PMID: 38983794
Numerous antibody biomarkers have been reported for cancer and atherosclerosis-related diseases. The major complications of atherosclerosis and diabetes mellitus (DM) are acute ischemic stroke (AIS), cardiovascular disease (CVD) and chronic...
10.
Tamura Y, Kumamaru H, Tsujino I, Suda R, Abe K, Inami T, et al.
Pharmaceuticals (Basel)
. 2024 May;
17(5).
PMID: 38794126
Pulmonary arterial hypertension (PAH) remains a significant challenge in cardiology, necessitating advancements in treatment strategies. This study explores the safety and efficacy of transitioning patients from beraprost to selexipag, a...